Ulka N. Vaishampayan, MBBS

Experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, look toward the future treatment paradigm of both clear cell and non–clear cell renal cell carcinoma.

Before closing out their discussion on renal cell carcinoma, key opinion leaders highlight efforts to optimize the management of non–clear cell disease with immunotherapy.

Contextualizing discussion with clinical trial data and real-world experience, expert hematologist-oncologists consider the role of adjuvant therapy in managing advanced RCC.

Shared insight from Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, on unmet needs in the setting of clear cell and non–clear cell renal cell carcinoma.

Key opinion leaders reflect on novel treatment modalities still under investigation for the management of advanced renal cell carcinoma.

Expert hematologist-oncologists share comprehensive perspective on an array of first-line clinical trials in the setting of advanced renal cell carcinoma.

A brief review of common adverse events inherent in the first-line management of advanced renal cell carcinoma and practical advice on how to mitigate treatment toxicity.

Opening their discussion on the advanced renal cell carcinoma treatment landscape, experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, identify cornerstone first-line regimens.